ROCEPHIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN (ROCEPHIN).
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
| Metabolism | Ceftriaxone is not metabolized in the liver; it is eliminated primarily via renal and biliary routes. Approximately 33-67% of the dose is excreted unchanged in the urine, and the remainder is excreted in the feces via bile. |
| Excretion | Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal. |
| Half-life | Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly. |
| Protein binding | 95% bound, primarily to albumin. |
| Volume of Distribution | 0.12-0.14 L/kg; reflects moderate tissue distribution, not extensive due to high protein binding. |
| Bioavailability | IM: 100% bioavailability; IV: 100%. |
| Onset of Action | IV: Immediate; IM: 1-2 hours after injection. |
| Duration of Action | Approximately 24 hours; allows once-daily dosing due to prolonged half-life and high protein binding. |
| Molecular Weight | 598.54 |
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR <10 mL/min: 1 g every 24 hours; no adjustment for GFR >=10 mL/min. |
| Liver impairment | No adjustment required for Child-Pugh A or B; insufficient data for Child-Pugh C; monitor if severe impairment. |
| Pediatric use | 50-75 mg/kg IV or IM once daily; maximum 2 g/day. For meningitis: 100 mg/kg once daily (max 4 g). |
| Geriatric use | No specific adjustment; dose based on renal function (creatinine clearance) as per adult guidelines. |
| 1st trimester | Animal studies have not shown teratogenic effects; no adequate human studies; use only if clearly needed. |
| 2nd trimester | Considered safe; no known fetal risk in human studies. |
| 3rd trimester | Considered safe; no known fetal risk in human studies. |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN (ROCEPHIN).
| Placental transfer | Ceftriaxone crosses the placenta and achieves therapeutic concentrations in fetal serum. |
| Breastfeeding | Ceftriaxone is excreted in small amounts in breast milk. Levels are low and not expected to cause adverse effects in the nursing infant. Use caution in infants with hyperbilirubinemia or those receiving calcium-containing IV solutions. |
| Lactation Rating |
■ FDA Black Box Warning
Anaphylactic reactions: Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients on penicillin therapy. Before therapy with ceftriaxone is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs.
| Serious Effects |
Hypersensitivity to cephalosporins or any componentHyperbilirubinemic neonates, especially those with jaundice or those receiving calcium-containing IV solutionsPremature neonates (due to risk of kernicterus)
| Precautions | Hypersensitivity reactions: Cross-allergenicity with penicillins and other beta-lactams., Gallbladder pseudolithiasis: Ceftriaxone-calcium precipitates may form, causing biliary sludge or stones., Clostridioides difficile-associated diarrhea (CDAD): May range from mild diarrhea to fatal colitis., Hemolytic anemia: Immune-mediated hemolytic anemia reported, often fatal; discontinue if anemia develops., Neonates: Risk of bilirubin encephalopathy due to displacement of bilirubin from albumin; avoid in hyperbilirubinemic neonates., Calcium-containing solutions: Avoid coadministration with calcium-containing IV solutions in neonates due to risk of fatal precipitation. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | Ceftriaxone crosses the placenta. Animal studies at doses up to 20 times the human dose showed no evidence of teratogenicity. In humans, large epidemiological studies have not demonstrated an increased risk of major birth defects after first-trimester exposure. However, because animal reproduction studies are not always predictive of human response, ceftriaxone should be used during pregnancy only if clearly needed. No known fetal risks in any trimester. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal allergic reactions, signs of superinfection, and for neonatal jaundice if used near term (ceftriaxone can displace bilirubin from albumin). |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data on fertility impairment. |
| Food/Dietary |
| No significant food interactions. Administer without regard to meals. However, avoid alcohol during treatment and for 48 hours after completion due to possible disulfiram-like reaction (headache, flushing, nausea). |
| Clinical Pearls | 1. Ceftriaxone (Rocephin) has high protein binding (>90%) and a long half-life (5.8-8.7 hours) allowing once-daily dosing. 2. It achieves excellent CNS penetration only when meninges are inflamed; use for meningitis but not for routine CNS infections. 3. Avoid in neonates with hyperbilirubinemia due to bilirubin displacement risk. 4. Do not co-administer with calcium-containing IV solutions (e.g., Ringer's lactate) due to precipitation risk; use dedicated line or flush with NS. 5. Monitor for biliary sludge/pseudolithiasis, especially in children and high-dose therapy. |
| Patient Advice | Complete the entire course even if you feel better. · Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing. · This medication may cause diarrhea, which can be severe (C. difficile). Contact your doctor if watery or bloody stools occur. · Avoid alcohol while taking this medication and for 48 hours after the last dose to prevent disulfiram-like reaction. · Inform your doctor if you are pregnant, breastfeeding, or have a history of kidney or liver disease. |